Lipocalin-2 expression in papillary thyroid carcinoma and its association with clinicopathological characteristics
European Archives of Oto-Rhino-Laryngology · 2025
DOI: 10.1007/s00405-024-08954-w ↗Kurz gefasst
Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2025. Verfasst von Mustafa Alkaya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of ENT, Kayseri City Training and Research Hospital, Kayseri, Turkey. alkaya.mustafa90@gmail.com. Hauptthemen laut MEDLINE: Lipocalin-2, Thyroid Neoplasms, Thyroid Cancer, Papillary, Goiter, Nodular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The present study aimed to assess Lipocalin-2 (LCN2) expression in patients with papillary thyroid cancer (PTC) and to compare it with multinodular goitre (MNG). We also investigated the correlation between LCN2 expression and clinicopathologic characteristics. METHODS: This retrospective study included 63 surgically treated adult patients with papillary carcinoma and 65 adult patients with a MNG. Age, gender, physical, radiological and histopathological examinations, and surgical data of the patients were extracted from the hospital records. Size, histological subtype, capsule invasion, multifocality, extrathyroidal extension (ETE), lymph node metastasis (LNM), and immunohistochemical (IHC) studies of the tumour were recorded from the final histopathological reports of patients with PTC. The patient groups were compared in terms of LCN2 expression. The relationships between LCN2 expression and clinicopathological and other IHC parameters were also evaluated in patients with PTC. RESULTS: LCN2 expression was significantly higher in the PTC group than in the control group. No significant correlation was demonstrated between LCN2 expression and the presence of multifocal disease, capsular invasion, vascular invasion, ETE, and LNM. There was a moderate positive correlation between LCN2 and human bone marrow endothelial cell marker-1 (HBME-1) expressions, however, no correlation was found between LCN2 and cytokeratin-19 (CK19), CD56, and galectin-3. CONCLUSION: LCN2 expression may be a useful biomarker in differentiating benign and malignant lesions of the thyroid gland; however, its expression pattern may not be associated with clinicopathologic characteristics of the PTC and should be investigated in further studies with larger clinical samples.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of ENT, Kayseri City Training and Research Hospital, Kayseri, Turkey. alkaya.mustafa90@gmail.com.
- Halil Şıvgın State Hospital, Cumhuriyet Mh., Ankara Blv. No:54, 06760, Çubuk/Ankara, 05300, Turkey. alkaya.mustafa90@gmail.com.
- Department of ENT, Kayseri City Training and Research Hospital, Kayseri, Turkey.
- Department of Pathology, Kayseri City Training and Research Hospital, Kayseri, Turkey.
- Department of Nuclear Medicine, Kayseri City Training and Research Hospital, Kayseri, Turkey.
Zitieren
APA
Alkaya, M., Bayram, A., Yaşar, M., Doğan, M., & Gençer, H. (2025). Lipocalin-2 expression in papillary thyroid carcinoma and its association with clinicopathological characteristics. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-024-08954-w
Vancouver
Alkaya M, Bayram A, Yaşar M, Doğan M, Gençer H. Lipocalin-2 expression in papillary thyroid carcinoma and its association with clinicopathological characteristics. European Archives of Oto-Rhino-Laryngology. 2025. doi:10.1007/s00405-024-08954-w
BibTeX
@article{Alkaya2025,
author = {Alkaya, Mustafa and Bayram, Ali and Yaşar, Mehmet and Doğan, Merve and Gençer, Hümeyra},
title = {Lipocalin-2 expression in papillary thyroid carcinoma and its association with clinicopathological characteristics},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2025},
doi = {10.1007/s00405-024-08954-w}
}
EUVIMED